BRPI0416238A - compostos, processo para a sua preparação, composição farmacêutica que compreende os mesmos, uso dos compostos e métodos para o tratamento e/ou a prevenção de doenças que são moduladas por ppar(delta) e/ou agonistas ppar(alfa) - Google Patents
compostos, processo para a sua preparação, composição farmacêutica que compreende os mesmos, uso dos compostos e métodos para o tratamento e/ou a prevenção de doenças que são moduladas por ppar(delta) e/ou agonistas ppar(alfa)Info
- Publication number
- BRPI0416238A BRPI0416238A BRPI0416238-2A BRPI0416238A BRPI0416238A BR PI0416238 A BRPI0416238 A BR PI0416238A BR PI0416238 A BRPI0416238 A BR PI0416238A BR PI0416238 A BRPI0416238 A BR PI0416238A
- Authority
- BR
- Brazil
- Prior art keywords
- ppar
- compounds
- agonists
- modulated
- preparation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Ceramic Engineering (AREA)
- Hematology (AREA)
- Manufacturing & Machinery (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Materials Engineering (AREA)
- Endocrinology (AREA)
- Structural Engineering (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
"COMPOSTOS, PROCESSO PARA A SUA PREPARAçãO, COMPOSIçãO FARMACêUTICA QUE COMPREENDE OS MESMOS, USO DOS COMPOSTOS E MéTODOS PAPA O TRATAMENTO E/OU A PREVENçãO DE DOENçAS QUE SãO MODULADAS POR PPAR<sym> E/OU AGONISTAS PPAR<244>". A presente invenção refere-se a compostos da fórmula: em que um de R¬ 6¬, R¬ 7¬ e R¬ 8¬ é e X, Y¬ 1¬ a Y¬ 4¬, R¬ 1¬ a R¬ 14¬ e n são conforme definido na descendentemente, e a todos os enantiómeros e seus sais e/ou ésteres aceitáveis do ponto de vista farmacêutico. A invenção se refere ainda a composições farmacêuticas contendo tais compostos, a um processo para a preparação dos mesmos e ao uso dos mesmos para o tratamento e/ou a prevenção de doenças que são moduladas por PPAR<sym> e/ou agonistas PPAR<244>.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03104083 | 2003-11-05 | ||
PCT/EP2004/012197 WO2005049606A1 (en) | 2003-11-05 | 2004-10-28 | Heteroaryl derivatives as ppar activators |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0416238A true BRPI0416238A (pt) | 2007-01-02 |
Family
ID=34530792
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0416238-2A BRPI0416238A (pt) | 2003-11-05 | 2004-10-28 | compostos, processo para a sua preparação, composição farmacêutica que compreende os mesmos, uso dos compostos e métodos para o tratamento e/ou a prevenção de doenças que são moduladas por ppar(delta) e/ou agonistas ppar(alfa) |
Country Status (13)
Country | Link |
---|---|
US (1) | US6995263B2 (pt) |
EP (1) | EP1682535A1 (pt) |
JP (1) | JP2007509996A (pt) |
KR (1) | KR100761615B1 (pt) |
CN (1) | CN100509802C (pt) |
AR (1) | AR046228A1 (pt) |
AU (1) | AU2004291259A1 (pt) |
BR (1) | BRPI0416238A (pt) |
CA (1) | CA2543239A1 (pt) |
MX (1) | MXPA06004642A (pt) |
RU (1) | RU2367659C2 (pt) |
TW (1) | TW200530223A (pt) |
WO (1) | WO2005049606A1 (pt) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE602004016162D1 (de) * | 2003-07-02 | 2008-10-09 | Hoffmann La Roche | Indol-derivate, die durch einen thiazol ring substoren |
WO2005110416A2 (en) * | 2004-05-08 | 2005-11-24 | Neurogen Corporation | 4,5-disubstituted-2-aryl pyrimidines |
US7405236B2 (en) * | 2004-08-16 | 2008-07-29 | Hoffman-La Roche Inc. | Indole derivatives comprising an acetylene group |
CN101166725A (zh) * | 2005-02-25 | 2008-04-23 | 武田药品工业株式会社 | 吡啶基乙酸化合物 |
NZ568946A (en) * | 2005-12-29 | 2010-07-30 | Lexicon Pharmaceuticals Inc | Multicyclic amino acid derivatives and methods of their use |
US7897763B2 (en) | 2005-12-29 | 2011-03-01 | Lexicon Pharmaceuticals, Inc. | Process for the preparation of substituted phenylalanines |
US7855291B2 (en) | 2005-12-29 | 2010-12-21 | Lexicon Pharmaceuticals, Inc. | Process for the preparation of substituted phenylalanines |
US20080202239A1 (en) * | 2007-02-28 | 2008-08-28 | Fazzio R Shane | Piezoelectric acceleration sensor |
MX2010001938A (es) * | 2007-08-24 | 2010-03-11 | Lexicon Pharmaceuticals Inc | Metodos para preparar compuestos basados en 4-fenil-6-(2,2,2-trifl uoro-1-feniletoxi)pirimidina. |
DE102007042754A1 (de) | 2007-09-07 | 2009-03-12 | Bayer Healthcare Ag | Substituierte 6-Phenylnikotinsäuren und ihre Verwendung |
DE102007061757A1 (de) | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | Substituierte 2-Phenylpyrimidin-5-carbonsäuren und ihre Verwendung |
US7750027B2 (en) * | 2008-01-18 | 2010-07-06 | Oxagen Limited | Compounds having CRTH2 antagonist activity |
CN103044310B (zh) * | 2013-01-18 | 2015-02-04 | 贵阳医学院 | 二氢吲哚-3-乙酸衍生物、其制备方法以及在药物中的应用 |
GB201407807D0 (en) | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
GB201407820D0 (en) | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
CN106310173A (zh) * | 2016-08-24 | 2017-01-11 | 厦门三川利生物科技有限公司 | 含过氧化物酶体增殖物激活受体多维果酸醇及其制备方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2163150B (en) * | 1984-07-19 | 1988-05-25 | Sandoz Ltd | 3-aminopropoxyaryl derivatives |
US6369067B1 (en) * | 1997-10-27 | 2002-04-09 | Dr. Reddy's Research Foundation | Monocyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them |
ATE362468T1 (de) * | 2000-07-25 | 2007-06-15 | Merck & Co Inc | N-substituierte indole mit anwendung in der behandlung von diabetes |
CZ20033328A3 (cs) * | 2001-06-07 | 2004-06-16 | Eli Lilly And Company | Modulátory receptorů aktivovaných proliferátory peroxisomů (PPAR) |
WO2003018553A1 (en) * | 2001-08-29 | 2003-03-06 | Warner-Lambert Company Llc | Oral antidiabetic agents |
TWI231757B (en) | 2001-09-21 | 2005-05-01 | Solvay Pharm Bv | 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity |
US20040267028A1 (en) | 2001-09-24 | 2004-12-30 | Smith Roger A | Preparation and use of pyrrole derivatives for treating obesity |
GT200200188A (es) | 2001-09-24 | 2003-06-25 | Preparacion y uso de derivados de imidazol para el tratamiento de la obesidad | |
US6867224B2 (en) * | 2002-03-07 | 2005-03-15 | Warner-Lambert Company | Compounds that modulate PPAR activity and methods of preparation |
US6875780B2 (en) * | 2002-04-05 | 2005-04-05 | Warner-Lambert Company | Compounds that modulate PPAR activity and methods for their preparation |
WO2004092131A1 (en) * | 2003-01-06 | 2004-10-28 | Eli Lilly And Company | Indole derivatives as ppar modulators |
CA2512883A1 (en) * | 2003-02-14 | 2004-09-02 | Eli Lilly And Company | Sulfonamide derivatives as ppar modulators |
US7244763B2 (en) * | 2003-04-17 | 2007-07-17 | Warner Lambert Company Llc | Compounds that modulate PPAR activity and methods of preparation |
-
2004
- 2004-10-28 RU RU2006119503/04A patent/RU2367659C2/ru not_active IP Right Cessation
- 2004-10-28 CN CNB2004800328716A patent/CN100509802C/zh not_active Expired - Fee Related
- 2004-10-28 KR KR1020067008796A patent/KR100761615B1/ko not_active IP Right Cessation
- 2004-10-28 EP EP04790967A patent/EP1682535A1/en not_active Withdrawn
- 2004-10-28 WO PCT/EP2004/012197 patent/WO2005049606A1/en active Application Filing
- 2004-10-28 AU AU2004291259A patent/AU2004291259A1/en not_active Abandoned
- 2004-10-28 JP JP2006538705A patent/JP2007509996A/ja active Pending
- 2004-10-28 MX MXPA06004642A patent/MXPA06004642A/es active IP Right Grant
- 2004-10-28 BR BRPI0416238-2A patent/BRPI0416238A/pt not_active IP Right Cessation
- 2004-10-28 CA CA002543239A patent/CA2543239A1/en not_active Abandoned
- 2004-10-29 US US10/978,144 patent/US6995263B2/en not_active Expired - Fee Related
- 2004-11-03 AR ARP040104044A patent/AR046228A1/es unknown
- 2004-11-04 TW TW093133672A patent/TW200530223A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
CN100509802C (zh) | 2009-07-08 |
JP2007509996A (ja) | 2007-04-19 |
KR100761615B1 (ko) | 2007-10-04 |
US20050096353A1 (en) | 2005-05-05 |
MXPA06004642A (es) | 2006-06-27 |
US6995263B2 (en) | 2006-02-07 |
CN1878768A (zh) | 2006-12-13 |
CA2543239A1 (en) | 2005-06-02 |
AR046228A1 (es) | 2005-11-30 |
RU2367659C2 (ru) | 2009-09-20 |
TW200530223A (en) | 2005-09-16 |
KR20060086384A (ko) | 2006-07-31 |
RU2006119503A (ru) | 2007-12-27 |
EP1682535A1 (en) | 2006-07-26 |
WO2005049606A1 (en) | 2005-06-02 |
AU2004291259A1 (en) | 2005-06-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0416283A (pt) | compostos, processo para a fabricação de compostos, composição farmacêutica, método para o tratamento e/ou prevenção de doenças que são moduladas por agonistas de ppar(delta) e/ou ppar(alfa) e uso destes compostos | |
BRPI0416238A (pt) | compostos, processo para a sua preparação, composição farmacêutica que compreende os mesmos, uso dos compostos e métodos para o tratamento e/ou a prevenção de doenças que são moduladas por ppar(delta) e/ou agonistas ppar(alfa) | |
BR0212008A (pt) | Uso de um composto ou de um sal, solvato ou pró-medicamento deste, composição farmacêutica, composto ou um sal, solvato ou pró-medicamento deste, e, processo para a preparação deste | |
BR0213612A (pt) | Composto, composição farmacêutica, uso do composto e método para tratamento de doença ou condição | |
BR0210384A (pt) | Heteroarilas multicìclicas substituìdas por quinuclidinas para o tratamento de doença | |
BR0010555A (pt) | Inibidores de neuraminidases | |
BR0313266A (pt) | Compostos, respectivos processos de preparação e uso, formulação farmacêutica e métodos de prevenção e/ou tratamento de um distúrbio mediado pelo receptor de mglur5 e de inibição da ativação de receptores de mglur5 | |
BR0314314A (pt) | Derivados do éter 4-pirrolidina-fenil-benzìlico | |
BRPI0409227B8 (pt) | "composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)" | |
BRPI0514448A (pt) | derivados do ácido bifenil-oxiacético para uso no tratamento de doenças respiratórias | |
BR0215777A (pt) | Composto, método para preparar o mesmo, composição farmacêutica para prevenir e tratar cardioisquemia, cerebroisquemia, oclusão arterial cerebral e para melhorar microcirculação do cérebro, e uso do composto | |
BR0209957A (pt) | Composto, processo para a preparação de um composto, composição farmacêutica que compreende um composto, utilização desse composto e processo para o tratamento e profilaxia de artrite, diabetes, distúrbios alimentares e obesidade | |
BR0209821A (pt) | Compostos, processo para a manufatura desses compostos, composições farmacêuticas que compreendem os mesmos, processo para o tratamento e/ou profilaxia de enfermidades e utilização dos compostos | |
BR0113989A (pt) | Compostos, composições farmacêuticas, processo para a preparação de uma composição farmacêutica, e, uso de pelo menos um dos compostos | |
BR9509683A (pt) | Compostos e processos para tratar uma condição clínica em um mamífero para tratar uma condição hiperlipidêmica em um manífero e para a preparação de um composto | |
BR0215240A (pt) | Derivados de calcona e seu uso no tratamento de doenças | |
BR0209431A (pt) | Novos compostos de 4-anilinoquinolino-3-carboxamidas | |
BRPI0409627A (pt) | 2-hidróxi-3-diaminoalcanos de fenacila | |
BR0309012A (pt) | Uso de um composto, formulação farmacêutica, composto, composição farmacêutica, e, processo para a preparação de um composto | |
BRPI0512252A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, formulação farmacêutica, uso de um composto, método de tratamento de uma doença, produto combinado, e, processo para a preparação de um composto | |
BRPI0718862B8 (pt) | composto, composição farmacêutica que o contém e uso do composto | |
BRPI0417833A (pt) | novos derivados de benzofurano, os quais podem ser usados na profilaxia ou tratamento de distúrbios relacionados com o receptor 5-ht6 | |
BRPI0719920B8 (pt) | derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmo e composto intermediário | |
BR0310050A (pt) | Derivados de cetolida 6-11 bicìclicas, composições farmacêuticas e processos referentes aos mesmos | |
BRPI0607214B8 (pt) | derivados de 2-(4-cianofenilamino)pirimidina inibidores de hiv, composição farmacêutica que os compreende e seus processos de preparação |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08F | Application fees: application dismissed [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012. |